Last edition
News about
Lonza Expands TheraPEAK Product Portfolio, Launches AmpliCell Cytokines and TheraPEAK 293-GT Medium
Switzerland-based Lonza has expanded its GMP solutions for cell and gene therapy with the launch of TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium.
Merck Expands Tulisokibart Phase-2(b) Trials Across Three Inflammatory Diseases
Tulisokibart is an investigational anti-TL1A monoclonal antibody currently in Phase-3 trials for Ulcerative Colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial spondyloarthritis and Rheumatoid Arthritis.
Biocon and Carnegie Secure Tentative FDA Approval for Rifaximin Tablets
Biocon Pharma, a wholly owned subsidiary of Biocon Ltd., in partnership with Carnegie Pharmaceuticals, has received tentative approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Rifaximin Tablets, 550 mg.
Snowman Logistics Expands Cold Chain Network with New Temperature-Controlled Facility in Pune
Snowman Logistics has announced the commencement of construction of a new temperature-controlled warehouse facility in Pune, being developed under the Built-to-Suit (BTS) model by Whitecastle Infra.
Eli Lilly and Company has announced plans to invest more than USD 1 billion over the next several years to expand its contract manufacturing footprint in India, aimed at enhancing global access to its innovative medicines.
Clearmind Biomedical Signs US Distribution Agreement with Sutter Medical Technologies USA
Clearmind Biomedical has partnered with Sutter Medical to exclusively distribute its 510(k)-cleared Neuroblade Neuro-Endoscope System in the US, advancing treatment for intracerebral hemorrhage—one of the most severe and hard-to-treat stroke types.
Hikma, Celltrion Deepen Ties to Boost Biosimilar Access in Middle East and North Africa
British multinational pharmaceutical company Hikma Pharmaceuticals has signed new exclusive licensing agreements with its long-standing partner, South Korea’s Celltrion, covering the Middle East and North Africa (MENA) region.
Zydus Receives USFDA Approval for Deflazacort Oral Suspension
Zydus stated that deflazacort oral suspension will be produced at Doppel, Italy.
Avobis Bio’s lead therapeutic, AVB-114, has received FDA’s RMAT designation for Crohn’s perianal fistulas, building on its Fast Track status to accelerate development with enhanced regulatory support and guidance.
Onco3R Therapeutics Advances Phase 1 Trial of Novel SIK3 Inhibitor Targeting Autoimmune Diseases
Pierre Raboisson, CEO and Founder of Onco3R Therapeutics, said that the final results of the Phase 1 trial of O3R-5671 are expected in the first half of 2026.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy